Crispr Therapeutics (NASDAQ:CRSP) had its price target boosted by Roth Capital from $65.00 to $100.00 in a research note published on Tuesday, November 19th, The Fly reports.
CRSP has been the topic of several other reports. BidaskClub upgraded shares of Crispr Therapeutics from a hold rating to a buy rating in a report on Friday, November 15th. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. ValuEngine upgraded shares of Crispr Therapeutics from a sell rating to a hold rating in a research note on Friday, November 1st. Needham & Company LLC restated a buy rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a report on Wednesday, July 31st. Finally, Barclays upped their target price on Crispr Therapeutics from $59.00 to $62.00 and gave the stock an overweight rating in a report on Tuesday, July 30th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $69.54.
NASDAQ:CRSP opened at $70.71 on Tuesday. The firm has a 50-day moving average price of $54.12 and a two-hundred day moving average price of $47.22. The company has a market capitalization of $3.95 billion, a P/E ratio of -20.56 and a beta of 3.30. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. On average, equities research analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 over the last 90 days. 21.40% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in CRSP. Nikko Asset Management Americas Inc. increased its position in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after acquiring an additional 1,430,364 shares during the period. ARK Investment Management LLC increased its position in shares of Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares in the last quarter. Orbimed Advisors LLC bought a new stake in shares of Crispr Therapeutics during the third quarter worth about $21,167,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares during the last quarter. 49.81% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Why is total return important?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.